Bennu Biotherapeutics

Bennubio has been established based on its determination in scientific exploration and the care for patients by gathering a team of scientists with the spirit of innovation. Focusing on pioneering research in the field of cell therapy, we have devoted ourselves to transform scientific achievements and develop innovative therapies for cancer and autoimmune diseases. The innovative technology platform and the gene editing methods developed by Bennubio will significantly alleviate T-cell exhaustion, increase T cell durability and functionality by overcoming the inhibitory effect of tumor microenvironment, so that patients can have a better prognosis. Our first product is a high-quality TIL product developed based on the innovative nu-TECH platform, which aims to at prevailing over the obstacle in solid tumor therapies and addressing clinical unmet needs. We are now in preparation for the first-in-human clinical study in 2023. In the future, we shall continue to expand in the field of T-cell therapies, including TIL, TCR-T and Treg products built on the evolving nu-GENE technology platform. With our distinctive expertise in the field of T cell therapy, Bennubio will stive in building a global pioneering production platform and innovative therapies through accelerated industrialization to bring hopes to all the patients. 毕诺济（上海）生物技术有限公司的成立是基于对科学探索的执着以及对病患需求的关怀，汇聚了一群拥有创新精神，求真求实的团队。我们专注于细胞治疗领域的前沿探索，致力于科研成果的临床转化，开发针对肿瘤和自体免疫性疾病的创新疗法。毕诺济开发的优化创新技术平台及基因编辑手段，能显著减缓T细胞耗竭，强化其持久性和杀伤力，从而克服肿瘤微环境的抑制性，实现患者更好的预后。 我们的第一个产品是由创新的nu-TECH平台而打造的高质量的TIL，专注于解决实体瘤的未满足临床需求，将于2023年进入临床实验。未来我们会在nu-GENE技术平台上继续拓展工程化TIL，TCR-T和Treg等T细胞领域。毕诺济将充分发挥长期积累的产学研优势，快速推进产业化，打造全球首创的产品线，为患者带来希望。 EMAIL: career@bennubiotx.com